Zacks Investment Research on MSN
Natera files Signatera CDx PMA with FDA for bladder cancer MRD test
Natera NTRA recently announced the submission of a premarket approval (PMA) application to the FDA for its Signatera CDx test ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test ...
Natera, Inc.'s revenue growth remains strong, driven by rapid adoption of Signatera, now covered by Medicare, which should provide recurring revenue and some competitive advantage. Litigation risks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results